The return of Ebola to Congo in May, causing 12 deaths in the area around Bikoro along the mighty Congo River, just 150 km from the major transport hub of Mbandaka, a city of over 1 million inhabitants, was foreseen but the message was not heeded. The resurgence of the disease, with 17 deaths from haemorrhagic fever, as reported by the WHO in June, was no surprise.
An unlicensed, but effective, vaccine was introduced but its storage requires temperatures between -60 C and -80 C, not particularly easy along the Equator! In the background are failed promises: clinics never developed in Sierra Leone and Liberia where some 8000 people died of the disease; many graves still remain unmarked; proper water supplies were never resourced; and transportation systems are back to their chaotic usualness.
Furthermore, stories are emerging of the misappropriation of c. US$5 million of aid money collected to deal with Ebola in Sierra Leone.
When it comes to infectious disease, the world seems to either go into panic mode or just dreams of ways of making more and more money. The serious issue of multiple drug resistance of more and more germs receives lip service. As highlighted by Littmann et al. 1 in an article already three years old, ethical issues are at the base. While they argue regarding resultant restrictions in individual liberty, their more important point concerns access of people to effective antibiotics and their effectiveness generally. Of course, this concern was spelt out over 70 years ago by Sir Alexander Fleming at his Nobel Prize lecture in 1945. Although he believed under-dosing would bring resistance, he realised certain bacteria and fungi were insensitive. The use of penicillin against these he described as a simple waste of time, effort and money. 2 The inappropriate usage of penicillin was, however, always a worry, plainly evident when it was labelled as the new wonder drug. The subsequent introduction of powerful antibiotics has suffered the same problem. In addition, drastic reduction in UN funding by America's Trump administration on the basis of its short-sighted ''America First'' policy might yet rebound on the US.
Happily, we publish a paper which suggests reverting to early generation antibiotics (and therefore lesserused drugs) may prove efficacious.
Nonetheless, while efforts have been made to limit the use of antibiotics in hospital care, their inappropriate use in general practice, or as over-the-counter medicines, remains unabated in many countries. Patients or their relatives also often demand antibiotics when there is no indication for their use and simply search online for their self-motivated cure themselves.
Furthermore, the distinction between use as prophylaxis and as treatment is still not widely fully understood by medical and nursing personnel. The World Health Organization (WHO) recommendations in this respect are vague: 'Prescribe and dispense the right antibiotic at the right dose for the right duration'. 3 More worrying, however, is the use of antibiotics in livestock. This concern was raised by Littman et al., but in the context of veterinary practice. Antibiotics are, however, now used as a commercial measure, and where battery production of chickens, for example, predicate a huge supply of prophylactic (or 'preventative') antibiotic use simply on financial grounds to keep up profit margins. Here may be a much greater potential source of rampant antibiotic resistance. This has been highlighted by the WHO 4 but perhaps without enough force.
The emergence of multi-drug resistant tuberculosis, 5 whether associated with HIV co-morbidity 6 or inadequate treatment in the Russian prison system, 7 is 'old hat', and that of the gonococcus already wellknown. 8 Now resistant syphilis has emerged. 9 Thus, the practice of unrestrained personal liberty, at least in matters of sexual continence, cannot be justified. John Donne had it right: 'No man is an Iland, intire of itselfe; every man is a peece of the Continent, a part of the maine' (sic). 10 
